{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:19:59Z","timestamp":1792120799737,"version":"4.4.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This pilot study assessed the safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794), a genetically modified autologous T-cell therapy targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1)\/L antigen family member 1 isoform A (LAGE-1a)\u2013positive myeloma cells, alone or in combination with pembrolizumab in patients with relapsed\/refractory multiple myeloma. Eligible patients expressed NY-ESO-1 and\/or LAGE-1a and either HLA-A\u221702:01, \u221702:05, or \u221702:06. Patients received lete-cel single infusion alone (arm 1) or with pembrolizumab (arm 2). 127 patients were screened, and 6 patients (3 per arm) were enrolled; patients in arm 1 and 2 received lete-cel alone, or with pembrolizumab, respectively. All patients exhibited grade 3\/4 cytopenias, which resolved or improved to grade 1. One patient (arm 1) had grade 3\/4 lete-cel\u2013related adverse events (AEs); 2 patients (arm 2) had grade 3\/4 AEs related to lete-cel and lymphodepletion. Three patients with grade 1\/2 cytokine release syndrome (CRS) exhibited elevated post\u2013lete-cel interleukin-6 levels versus those without CRS. Pooled overall response rate was 50% including 1 patient each with confirmed clinical response, very good clinical response, and partial response, and progression-free survival ranged from 1.3 to 5.2 months. Responders (arm 1: n = 1; arm 2: n = 2) had a time-to-response of 3 weeks, duration of response of 2.1 months. Two responders, but no nonresponders, exhibited elevated cytokine levels after lete-cel infusion. Lete-cel had a manageable safety profile and demonstrated clear but transient antitumor activity in patients with relapsed\/refractory multiple myeloma. This trial was registered at www.clinicaltrials.gov as #NCT03168438.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008460","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T16:10:29Z","timestamp":1671466229000},"page":"1168-1177","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed\/refractory multiple myeloma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"first","affiliation":[{"name":"1Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"2Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huff","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet S.","family":"Kapoor","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-1061","authenticated-orcid":false,"given":"Ioanna","family":"Eleftheriadou","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9844-9951","authenticated-orcid":false,"given":"Stefan","family":"Zajic","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Urbano","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Suchindran","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chisamore","sequence":"additional","affiliation":[{"name":"4Merck & Co, Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimson W.","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Faitg","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"5University of Maryland Greenebaum Comprehensive Cancer Center and School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"issue":"9","key":"2023090715334746200_bib1","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"2023090715334746200_bib2","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.3390\/cancers13236136","article-title":"Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2023090715334746200_bib3","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2023090715334746200_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"2023090715334746200_bib5","author":"ABECMA (idecabtagene vicleucel)","year":"2021"},{"key":"2023090715334746200_bib6","author":"CARVYKTI (ciltacabtagene autoleucel)","year":"2022"},{"issue":"1","key":"2023090715334746200_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12772","article-title":"T\u00a0cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol Rev"},{"issue":"8","key":"2023090715334746200_bib8","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma","volume":"8","author":"D'Angelo","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"2023090715334746200_bib9","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.4049\/jimmunol.176.12.7308","article-title":"Quantifying and imaging NY-ESO-1\/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors","volume":"176","author":"Purbhoo","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"2023090715334746200_bib10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"2023090715334746200_bib11","first-page":"2","article-title":"Prognostic impact of cancer\/testis antigen expression in advanced stage multiple myeloma patients","volume":"8","author":"Andrade","year":"2008","journal-title":"Cancer Immun"},{"issue":"3","key":"2023090715334746200_bib12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2006-04-014480","article-title":"Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation","volume":"109","author":"Atanackovic","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2023090715334746200_bib13","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.4049\/jimmunol.178.5.3307","article-title":"Cancer\/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis","volume":"178","author":"Condomines","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"2023090715334746200_bib14","first-page":"1","article-title":"Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy","volume":"11","author":"de Carvalho","year":"2011","journal-title":"Cancer Immun"},{"issue":"1","key":"2023090715334746200_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","article-title":"The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation","volume":"106","author":"Jungbluth","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2023090715334746200_bib16","first-page":"1156","article-title":"Genes encoding tumor-specific antigens are expressed in human myeloma cells","volume":"94","author":"van Baren","year":"1999","journal-title":"Blood"},{"issue":"10","key":"2023090715334746200_bib17","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"van Rhee","year":"2005","journal-title":"Blood"},{"issue":"Suppl 3","key":"2023090715334746200_bib18","first-page":"A1","article-title":"298 final analysis of the phase 1 trial of NY-ESO-1\u2013specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)","volume":"8","author":"D\u2019Angelo","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"13","key":"2023090715334746200_bib19","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/bloodadvances.2019000194","article-title":"Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma","volume":"3","author":"Stadtmauer","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"2023090715334746200_bib20","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"2023090715334746200_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/cancers13020164","article-title":"PD-L1\/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression","volume":"13","author":"Costa","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2023090715334746200_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"issue":"23","key":"2023090715334746200_bib23","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023090715334746200_bib24","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2023090715334746200_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4049\/jimmunol.2001357","article-title":"Engineering cancer antigen-specific T cells to overcome the immunosuppressive effects of TGF-beta","volume":"208","author":"Silk","year":"2022","journal-title":"J\u00a0Immunol"},{"key":"2023090715334746200_bib26","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0","author":"National Cancer Institute","year":"2009"},{"issue":"8","key":"2023090715334746200_bib27","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2023090715334746200_bib28","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"2023090715334746200_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"2023090715334746200_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"issue":"15 suppl","key":"2023090715334746200_bib31","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1200\/JCO.2021.39.15_suppl.11521","article-title":"Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid\/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): interim analysis","volume":"39","author":"D\u2019Angelo","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023090715334746200_bib32","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","article-title":"Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma","volume":"13","author":"Gyurdieva","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"2023090715334746200_bib33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/cells11030410","article-title":"Adoptive cellular therapy for multiple myeloma using CAR- and TCR-transgenic T cells: response and resistance","volume":"11","author":"Fuchsl","year":"2022","journal-title":"Cells"},{"key":"2023090715334746200_bib34","article-title":"Population coverage of HLA-A\u221702:01, \u221702:05, \u221702:06 across selected cancer types in the United States","volume":"9","author":"Patel","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"2023090715334746200_bib35","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2023090715334746200_bib36","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.17448","article-title":"Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: cohort 2 of the phase I KEYNOTE-023 study","volume":"194","author":"Moreau","year":"2021","journal-title":"Br J Haematol"},{"issue":"19","key":"2023090715334746200_bib37","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMp1803602","article-title":"Immunotherapy combinations in multiple myeloma - known unknowns","volume":"379","author":"Gormley","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/7\/1168\/2076722\/blooda_adv-2022-008460-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/7\/1168\/2076722\/blooda_adv-2022-008460-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T15:34:27Z","timestamp":1694100867000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/7\/1168\/493750\/Safety-and-efficacy-of-letetresgene-autoleucel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,4,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008460","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}